Dysregulated hemostasis in acute promyelocytic leukemia

Int J Hematol. 2024 Feb 11. doi: 10.1007/s12185-024-03708-0. Online ahead of print.ABSTRACTAcute promyelocytic leukemia (APL) is associated with a high incidence of early death, which occurs within 30 days of diagnosis. The major cause of early death in APL is severe bleeding, particularly intracranial bleeding. Although APL is known to be associated with activation of coagulation, hyperfibrinolysis, and thrombocytopenia, the precise mechanisms that cause bleeding have not yet been elucidated. I propose that a combination of four pathways may contribute to bleeding in APL: (1) tissue factor, (2) the urokinase plasminogen activator/urokinase plasminogen activator receptor, (3) the annexin A2/S100A100/tissue plasminogen activator, and (4) the podoplanin/C-type lectin-like receptor 2. A better understanding of these pathways will identify new biomarkers to determine which APL patients are at high risk of bleeding and allow the development of new treatments for APL-associated bleeding.PMID:38341391 | DOI:10.1007/s12185-024-03708-0
Source: International Journal of Hematology - Category: Hematology Authors: Source Type: research